Table 1.
Patient characteristics at different follow-up times. * p < 0.001 (previous time point, same group), ** p = 0.03 (previous time point, same group), ° p = 0.04 (group comparison).
| JAKi | Anti-Cellular bDMARDs | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | At 2nd Shot | 3-Month Follow-Up | Baseline | At 2nd Shot | 3-Month Follow-Up | |||||||||||||
| Av.obs | Av.obs. | Av.obs. | Av.obs. | Av. Obs. | Av. Obs. | |||||||||||||
| Female, n% | 26 | 23 | 88.46 | 26 | 21 | 80.76 | 26 | |||||||||||
| Age, years, mean (SD) | 26 | 55.61 | 13.26 | 26 | 59.30 | 9.67 | 26 | |||||||||||
| BMI, mean (SD) | 26 | 26.89 | 4.44 | 26 | 25.05 | 4.82 | 26 | |||||||||||
| DAS28, mean (SD) | 26 | 2.88 | 1.01 | 26 | 2.81 | 0.99 | 26 | 2.61 | 1.08 | 26 | 3.45 | 1.59 | 26 | 3.32 | 1.39 | 26 | 3.09 | 1.17 |
| Disease duration, months, mean (SD) | 26 | 63.85 ° | 59.03 | 26 | 97.88 ° | 82.48 | 26 | |||||||||||
| HAQ-DI, median (IQR) | 26 | 0.5 | 0.12–1.12 | 25 | 0.5 | 0.12–1.12 | 36 | 0.43 | 0.12–1.12 | 26 | 0.87 | 0.37–1.87 | 26 | 0.87 | 0.25–1.87 | 26 | 0.87 | 0.25–1.87 |
| RF positivity, n% | 26 | 19 | 73.08 | 26 | 14 | 53.85 | 26 | |||||||||||
| ACPA positivity, n% | 26 | 22 | 84.62 | 26 | 18 | 69.23 | 26 | |||||||||||
| Treatment line, median (IQR) | 26 | 2 | 1.0–3.0 | 26 | 2 | 1.0–3.0 | 26 | |||||||||||
| PDNeq, mg, mean(SD) | 26 | 2.28 ° | 2.25 | 26 | 3.75 ° | 3.70 | 26 | |||||||||||
| MTX combotherapy, n% | 26 | 13 | 50 | 26 | 9 | 34.62 | 26 | |||||||||||
| Previously reported HZ, n% | 26 | 0 | 0 | 26 | 2 | 7.69 | 26 | |||||||||||
| Anti-VZV IgG, miU/mL, mean (SD) | 26 | 843.96 | 584.87 | 26 | 2059.19 * | 876.62 | 26 | 2582.65 ** | 821.59 | 26 | 1000.66 | 717.35 | 26 | 2258.76 * | 897.07 | 26 | 2347.46 | 975.47 |
| DAS28 remission, n% | 26 | 10 | 38.46 | 26 | 11 | 42.30 | 26 | 14 | 53.84 | 26 | 9 | 34.61 | 26 | 9 | 34.61 | 26 | 9 | 34.61 |
| Fever, n% | 26 | 6 | 23.08 | 26 | 5 | 19.23 | ||||||||||||
| Myalgia, n% | 26 | 4 | 15.38 | 26 | 1 | 3.85 | ||||||||||||
| Headache, n% | 26 | 4 | 15.38 | 26 | 7 | 29.92 | ||||||||||||
| Lymphadenopathy, n% | 26 | 1 | 3.85 | 26 | 0 | 0 | ||||||||||||
| Sleep disorder, n% | 26 | 3 | 11.54 | 26 | 2 | 7.69 | ||||||||||||
| Injection site reactions (redness, swelling, skin thickening), n% | 26 | 21 | 80.77 | 26 | 24 | 92.31 | ||||||||||||
| Fatigue, n% | 26 | 8 | 30.77 | 26 | 5 | 19.23 | ||||||||||||
| Non-responders, n% | 26 | 1 | 3.85 | 26 | 0 | 0 | 26 | 2 | 7.69 | 26 | 2 | 7.69 | ||||||
Abbreviations: ACPA: Anti-Citrullinated Protein Antibody; BMI: Body Mass Index; CDAI: Clinical Disease Activity Index; csDMARDs: Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs; DAS28-ESR: Disease Activity Score on 28 joints with Erythrocyte Sedimentation Rate; HAQ-DI: Health Assessment Questionnaire-Disability Index MTX: Methotrexate; PDN: Prednisone; RF: Rheumatoid Factor; VZV: Varicella Zoster Virus.